INVENTIONS FOR LICENSE
MCL 1811.0: Agents for Treatment of Cognitive Disorders
Perry Renshaw, M.D., Ph.D., et al.
- Cognitive Disorders
- Treatment of Memory Loss
- Treatment of Dementia
Background and Description
Changes in the physical and chemical properties of the cell membrane can lead to changes in membrane fluidity, which in turn can have significant effects on membrane-linked functions such as ion transport and signal transduction. Use of a particular class of compounds, known to have an effect on one component of cell membranes, is proposed for the treatment of particular cognitive disorders where membrane fluidity appears to be an important factor in causing decreased brain cell function.
Potential Commercial Uses
The invention comprises a method of treating disorders like memory loss, cognitive impairment, and dementia, as well as depression, bipolar disorder and schizoaffective disorder. The method involves treatment of patients with agents which affect membrane fluidity. The cholesterol-lowering drugs known as the statins are believed to be particularly useful in the methods of the invention.
Publication and Patent Status
McLean Hospital is the owner of pending U.S. patent applications claiming this invention.
McLean Hospital is offering a worldwide exclusive license to this technology.
For more information, please contact:David J. Glass, Ph.D.
Senior Associate Director, Technology Transfer
McLean Hospital Research Administration
115 Mill Street
Belmont, MA 02478-9106
(617) 855-3825 - tel
(617) 855-3745 - fax